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Abstract
Background: During the last decade, medium-dose UVA1 phototherapy (50 J/cm2) has achieved
great value within the treatment of severe atopic dermatitis (AD). The purpose of our study was
to investigate to what extent UVA1 irradiation is able to modulate the status of protease activity
by the use of a monoclonal antibody labeling cathepsin G.
Methods: In order to further elucidate the mechanisms by which medium-dose UVA1 irradiation
leads to an improvement of skin status in patients with AD, biopsy specimens from 15 patients
before and after treatment were analyzed immunohistochemically for proteolytic activation.
Results: Compared to lesional skin of patients with AD before UVA1 irradiation, the number of
cells positive for cathepsin G within the dermal infiltrate decreased significantly after treatment.
The decrease of cathepsin G+ cells was closely linked to a substantial clinical improvement in skin
condition.
Conclusions: In summary, our findings demonstrated that medium-dose UVA1 irradiation leads
to a modulation of the expression of cathepsin G in the dermal inflammatory infiltrate in patients
with severe AD. Cathepsin G may attack laminin, proteoglycans, collagen I and insoluble
fibronectin, to provoke proinflammatory events, to degrade the basement membrane, to destroy
the tissue inhibitor of metalloproteinases and to increase the endothelial permeability. Therefore,
its down-regulation by UVA1 phototherapy may induce the reduction of skin inflammation as well
as improvement of the skin condition.
Background
Atopic dermatitis (AD) is a troublesome inflammatory
skin disease characterized by severe pruritus, typical ecze-
matous morphology and a chronic relapsing course. Pop-
ulation studies suggest that approximately 15% of the
population is already affected at some point during child-
hood [1,2].
Low-, medium- and high-dose UVA1 phototherapy have
been used successfully in the treatment of severe AD and
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other inflammatory Tcell-derived skin diseases [3–5]. Re-
cently, it has been demonstrated that UVA1 phototherapy
induces apoptosis of Tlymphocytes in lesional skin of AD
patients [6]. However, little has been investigated con-
cerning the exact in vivo mechanisms and pathways un-
derlying UVA1-induced improvement of skin status.
Cathepsin G, a serine protease, is often associated with the
degradation of cells and participates in a cascade of other
proteolytic proinflammatory pathways. Additionally,
cathepsin G increases the permeability of endothelial bar-
riers contributing to perivascular lymphocytic migration
and activation [7]. The pathogenesis of AD remains not
completely understood. Histologically, AD is recognized
by an inflammatory degradation of lesional skin com-
bined with an increased number of dermal Tlymphocytes,
predominantly Thelper cells of the so-called Th2 subtype
expressing a specific pathological cytokine pattern, eosi-
nophils, Langerhans cells, mast cells and other mononu-
clear cell populations [8]. Hence, we considered the
expression of cathepsin G as a potential marker indicating
UVA1-induced reduction of cutaneous inflammation. The
purpose of our study was to assess its expression in un-
treated and UVA1-irradiated skin in patients with AD. We
tried to investigate to what extent UVA1 irradiation is able
to modulate the status of protease activity by the use of a
monoclonal antibody labeling cathepsin G.
Patients and methods
Subjects
Biopsies were obtained from 15 patients with acute exac-
erbation of severe AD fulfilling the diagnostic criteria for
AD by Hanifin and Rajka with a medium SCORAD score
of 70.4 ± 13.1 (mean ± SD) [9,10]. Only patients with an
initial SCORAD score above 45 points and representative
involvement of the shoulders were assessed. All patients
gave informed consent for participation in the study. Ex-
clusion criteria were: patients with bacterial or viral super-
infection, pregnancy or lactation, oral antibiotics, external
corticoid therapy or antihistaminica within the last two
weeks, phototherapy within the last nine weeks, autoim-
mune disease with known photosensibility and a history
of polymorphous light eruption. Patients were treated
with whole body UVA1 cold light phototherapy consist-
ing of an exposure of 50 J/cm2 five times a week for three
weeks, resulting in a total of 15 treatment sessions and a
cumulative UVA1 dose of 750 J/cm2 each. The UVA1 irra-
diation equipment consisted of a Photomed CL 300000
liquid emitting wavelengths of 340–530 nm peaking at
370 and 380 nm. Additional therapy was restricted to the
use of emollients.
Cathepsin G and CD3 immunolabeling
In all subjects measurements were performed on skin site
of the right shoulder in order to minimize a sampling er-
ror. Initially and one hour following the 15th irradiation,
punch biopsies measuring 3 mm in diameter were taken
from an inflamed area (pretherapeutic) and an almost
completely healed site of former inflammation from the
same locality in a distance of >4 cm (posttherapeutic).
Taking consecutive sections, the alkaline phosphatase
anti-alkaline phosphatase (APAAP) technique using the
labeled streptavidin-biotin method (LSAB) was used to
enumerate cathepsin G+ cells at a dilution of 1:450 and
CD3+ cells at a dilution of 1:50. All proceedings followed
the given staining procedures [6].
Determination of immunopositive cells
In sites of perivascular infiltration, total skin-infiltrating
cells, CD3+ cells and cathepsin G+ cells were counted
'blind' separately in three view fields in a row (0.25 mm ×
0.25 mm each) directly below the dermoepidermal junc-
tion resulting in a length of 0.25 mm and 0.75 mm in
depth. In order to avoid a sampling error, all sections were
counted 'blind' for two times by the first observer. Addi-
tionally, a number of sections was randomly counted by a
second observer. In case of a difference of >2%, the sec-
tions had to be recounted by both observers. Positive cells
were expressed as a percentage of the dermal infiltrate per
field below the junction (mean ± SD).
In addition to histological cell count, all sections were
also evaluated for features of distribution pattern as well
as for morphological characteristics.
Statistics
Results are expressed as mean ± SD. After performing ex-
plorative data analysis, statistical evaluation, both for clin-
ical improvement and histological cell count, was
achieved using the Student's t-test for paired samples
(normal distribution). P-values < 0.05 were considered to
be significant.
Results
After three weeks of treatment the SCORAD score de-
creased significantly from 70.4 ± 13.1 to an average of
24.7 ± 12.1 (p < 0.0001). Prior to therapy an elevated per-
centage of cathepsin G+ cells, morphologically predomi-
nantly lymphocytes, could be detected within the dermal
inflammatory infiltrate in AD. The enhanced staining dis-
tribution could be reduced after UVA1 phototherapy (Fig.
1a,1b).
Referring to cathepsin G+ immunostaining before thera-
py, an average expression of 10.0% ± 0.051 within the 1st
field, 7.3% ± 0.059 within the 2nd field and 6.8% ± 0.077
within the 3rd field was assessed. Taken together, the per-
centage of cathepsin G+ cells was determined at a mean
grade of 8.0% ± 0.054 in sites of perivascular infiltration
in patients with AD (Fig. 1a, Fig. 2). After medium-doseBMC Dermatology 2002, 2 http://www.biomedcentral.com/1471-5945/2/12
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UVA1 phototherapy, a significant reduction of cathepsin
G+ cells towards a mean percentage of 5.3% ± 0.044 with-
in the 1st, 4.2% ± 0.039 within the 2nd and 2.6% ± 0.040
within the 3rd field below the junction could be observed.
The total average percentage of inflammatory cells stained
positive for cathepsin G immunolabeling was 4.1% ±
0.031 (p = 0.001; Fig. 1b, Fig. 2). Simultaneously, cathep-
sin G+ cells were counted with a mean of 8.8 ± 7.1 per
field before and 4.7 ± 4.1 after the UVA1 phototherapy.
The decrease of cathepsin G+ cells was accompanied by a
significant decrease of the absolute number of skin-infil-
trating cells (p < 0.05) indicating the strong effect of UVA1
irradiation on the dermal infiltration and a sharp decrease
after successful treatment. Thereby, CD3+ cells were de-
tected at a mean number of 38.9 ± 26.7 before and 15.5 ±
10.4 after the UVA1 phototherapy per field.
Apart from some occasional immunopositive dermal cells
within the papillary dermis, control sections of non-le-
sional skin of healthy volunteers were negative for cathe-
psin G (data not shown).
Discussion
In order to further elucidate the mechanisms by which
medium-dose UVA1 irradiation leads to an improvement
of skin status in patients with AD, biopsy specimens from
15 patients before and after treatment were analyzed im-
munohistochemically for features of proteolytic activa-
tion. As compared with lesional skin of patients with AD
before UVA1 irradiation, the percentage of cathepsin G+
Figure 1
Pre- and posttherapeutic labeling of cathepsin G in a representative patient with atopic dermatitis Cathepsin G
immunostaining in skin biopsies of a representative patient with severe atopic dermatitis before (a) and after (b) treatment.
Note the decrease of cathepsin G+ inflammatory cells (b) after 3 weeks of medium-dose UVA1 phototherapy with a cumula-
tive dose of 750 J/cm2 (original magnification, ×  200).BMC Dermatology 2002, 2 http://www.biomedcentral.com/1471-5945/2/12
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cells within the dermal infiltrate decreased significantly
after treatment. The relative decrease of cathepsin G+ cells
was closely linked to a substantial clinical improvement
of skin condition and a significant decrease of the dermal
lymphocytic infiltrate. As both biopsies were taken from
the same localization no remarkable differences concern-
ing histological characteristics were expected. Neverthe-
less, intraindividual variation with body site cannot be
completely excluded. In order to prevent an effect on the
cellular infiltrate of the second biopsy by the vicinity of
the first biopsy before treatment, biopsies were taken in a
distance of at least 4 cm [6].
Cathepsins comprise a family of proteolytic enzymes,
which are normally present in most human cells and par-
ticularly neutrophils. Beside the participation of cathep-
sins concerning tumor invasion and metastases, cathepsin
G incorporates widespread effects on direct proteolytic
cascades and inflammation. Additionally, cathepsin G in-
itiates or participates in a cascade of other proteolytically
destructive processes [11,12]. The serine protease is
known to attack proteoglycans, insoluble fibronectin, col-
lagen I and laminin, which also have proinflammatory
properties themselves. Moreover, cathepsin G obtains the
potential to induce proinflammatory events, to degrade
the basement membrane as well as to increase the perme-
ability of endothelial barriers contributing to further di-
rect and indirect injury, chemotaxis, migration and
activation of Tlymphocytes [13,14]. Another characteristic
of cathepsin G is the destruction of the tissue inhibitor of
metalloproteinases (TIMP), which inhibits the activity of
metalloproteinases and may therefore protect collagen
Figure 2
Pre- and posttherapeutic changes of dermal cathepsin G expression Boxplot diagram of the differences between pre-
and posttherapeutic percentages of cathepsin G+ cells in patients with severe atopic dermatitis (n = 15) following medium-dose
UVA1 phototherapy. Black bar = median, whisker = range, triangles = outliers.
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and other macromolecules from a possible degradation
[15], probably interfering with the UVA1-induced reduc-
tion of dermal collagen due to an increase of the colla-
genase I activity [16]. Interestingly, cathepsin G has
recently been found to participate in the apoptotic cas-
cades by cleaving the hbrm protein [17].
In summary, our data demonstrate that medium-dose
UVA1 irradiation of 50 J/cm2 is able to modulate signifi-
cantly the expression of cathepsin G in dermal skin infil-
trating cells in AD patients. The significant decrease of
cathepsin G+ was accompanied by an eminent reduction
of dermal Tcells (CD3+). Taking morphological character-
istics, staining pattern as well as consecutive sections (im-
munolabeling of CD3 and cathepsin G) into
consideration, the majority of cathepsin G+ cells may ob-
viously be contributed to dermal CD3+ lymphocytes. Nev-
ertheless, as most human cells i.e. neutrophils are able to
express cathepsin G, a synergistic interference by different
cell types simultaneously expressing cathepsin G cannot
be completely excluded. Additionally, by comparing per-
centages of cathepsin G+ cells based on the absolute
number of skin-infiltrating cells per field, it is unlikely
that the reduced expression of cathepsin G identified in
the post-UVA1 specimens might simply reflect an overall
decrease in the number of inflammatory cells within the
dermis. Even though we propose a direct effect of UVA1 ir-
radiation on the expression of cathepsin G, the reduction
of immunopositive might also be due to a reduction of
other inflammatory cells or a noncytolytic alteration in
mediator release. However, as the serine protease cathep-
sin G is thought to induce an inflammatory reaction asso-
ciated with various proteolytic degradations, its down-
regulation following UVA1 phototherapy may contribute
to the reduction of skin inflammation combined with the
remarkable improvement of the skin status. However, fur-
ther clinical trials are required in order to verify our data
in a larger number of patients.
Conclusions
Based on our results, we conclude that serial medium-
dose UVA phototherapy significantly decreases the expres-
sion of cathepsin G as a potential marker indicating pro-
teolytic activity in patients suffering from severe AD in
vivo. As cathepsin G is involved in a variety of destructive
pathways, we propose a correlation between the improve-
ment of clinical symptoms and the down-regulation of
pro-inflammatory events in lesional skin by the treatment
with medium-dose UVA1 irradiation.
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